Drugs / SNK02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05990920 | Aug 2023 → Apr 2024 | metastatic malignant neoplasm, refractory malignant neoplasm | NKGen Biotech, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2024-06-12 | NKGen Biotech, Inc. | Results NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 nkgenbiotech.com ↗
Dr. Song also provided an update on the Company’s initial Phase 1 results using SNK02 to treat patients with advanced refractory solid tumors. |
| 2024-05-23 | NKGen Biotech, Inc. | Results NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting nkgenbiotech.com ↗
In this Phase 1 trial, the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02. |
| 2023-10-12 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, 동종 NK세포치료제 고형암 임상 1상 승인 nkgenbiotechkorea.com ↗
엔케이맥스가 고형암 환자를 대상으로 자사의 동종 NK세포치료제(SNK02) 임상 1상을 위한 임상시험계획(IND)을 국내 식품의약품안전처(식약처)로부터 승인받았다고 11일 밝혔다. |
| 2023-03-06 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, 동종 NK세포치료제 고형암 타깃 임상 1상 신청 nkgenbiotechkorea.com ↗
엔케이맥스는 식품의약품안전처에 고형암 환자를 대상으로 한 동종 NK세포치료제(SNK02)를 투여하는 임상시험계획(IND)을 신청했다고 3일 밝혔다. |
| 2022-10-17 | NKGen Biotech, Inc. | Regulatory NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors nkgenbiotech.com ↗ |
| 2022-09-01 | NKMAX Co., Ltd. | Regulatory 엔케이맥스, 슈퍼NK 세포치료제 위암 대상 국내 1/2a상 신청 nkgenbiotechkorea.com ↗
엔케이맥스는 동종 NK(자연살해) 세포치료제 'SNK02'의 국내 1/2a상 임상신청계획서(IND)를 식품의약품안전처에 제출했다고 22일 밝혔다. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNK02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05990920 ↗ |
| Modality | Cell therapy | “ex vivo expanded allogeneic NK cells” NCT05990920 ↗ |
| Route | Intravenous | “IV injection” NCT05990920 ↗ |